COMMUNIQUÉS West-GlobeNewswire

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
27/04/2026
A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6) Persistence observed through [...]
Intellia Announces Proposed Public Offering of Common Stock
27/04/2026
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
27/04/2026
Sheba medical center researcher to present NurExone’s exosome optic nerve regeneration work at ISCEV@Denver TORONTO, Ontario and HAIFA, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) ( [...]
Virbac : Communiqué de mise à disposition du Rapport Annuel de Virbac au 31 décembre 2025
27/04/2026
Communiqué de mise à disposition du Rapport Annuel de Virbac au 31 décembre 2025. Le Groupe annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son Rapport Annuel au format [...]
EssilorLuxottica: Disclosure of transactions in own shares
27/04/2026
Disclosure of transactions in own shares Paris, France (April 27, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2025, EssilorLuxottica declares that on [...]
AB Science annonce un accord final sur la renégociation des modalités de remboursement de ses emprunts avec l’ensemble de ses créanciers financiers
27/04/2026
COMMUNIQUE DE PRESSE AB SCIENCE annonce un accord final sur la renégociation des modalités de remboursement de ses emprunts avec l’ensemble de ses créanciers financiers AB Science est parvenue à un accord définitif avec [...]
IBA – ACQUISITION OF OWN SHARES
27/04/2026
Louvain-la-Neuve, Belgium, April 27 th , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
27/04/2026
Déclaration de transactions sur actions propres Paris, France (27 avril 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2025, EssilorLuxottica déclare que le 24 avril 2026, les [...]
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
27/04/2026
Ghent, Belgium, April 27, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE - REGULATED INFORMATION 27 April 2026, 6:00 pm CEST Ghent, Belgium, 27 April 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " [...]
Virbac : Rapport Annuel Virbac au 31 décembre 2025 (ESEF)
27/04/2026
Veuillez trouver le Rapport Annuel du Groupe au format ESEF au 31 décembre 2025 Pièce jointe Rapport_Annuel_Virbac_2025_XBRL
IBA – ACQUISITION D’ACTIONS PROPRES
27/04/2026
Louvain-la-Neuve, Belgique, 27 avril 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
27/04/2026
PRESS RELEASE AB SCIENCE announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors AB Science has reached a final agreement with its financial creditors [...]
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
27/04/2026
WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced continued progress within its artificial intelligence initiative, Tevogen.AI, including [...]
Virbac : Public release of Virbac Annual Report at 31 December 2025.
27/04/2026
Public release of Virbac Annual Report at 31 December 2025. The Group released and filed its 2025 Annual Report with the French “Autorité des marchés financiers”, at the ESEF format. Additionally, the report is attached [...]
AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance
27/04/2026
Global CDMO recognized for exceptional quality systems and regulatory track record; named finalist in Excellence in Client Service & Partnership and Manufacturing Operations categories SEATTLE, April 27, 2026 (GLOBE [...]
SBC Medical Announces Full-Scale Rollout of Aesthetic Healthcare-Focused Interpretation App "Talk Bridge" Across All Shonan Beauty Clinic Locations
27/04/2026
Strengthening English-Speaking Customer Experience Through Interpretation Infrastructure, Specialized Talent, and Digital Marketing IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings [...]
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
27/04/2026
Definitive Agreement Targeted for Execution by June 2026 TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) (“PharmAla” or the “Company”), a biotechnology company [...]
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
27/04/2026
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc. (NASDAQ: BLTE), (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics [...]
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
27/04/2026
Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis Once-daily ZORYVE cream was well tolerated with a [...]

Pages